

# The Impact of Infusion Pumps on Subcutaneous Immunoglobulin Therapy Adherence for Chronic Inflammatory Demyelinating Polyneuropathy: Insights from a Large-Scale Database Analysis

Jasmin Bosshard, MSc; Anna Majapuro-Hirvonen, RN, BSc, MBA; and Brent Rutland, MPH, MBA. Email: jbosshard@korumedical.com

## INTRODUCTION


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an Immune-mediated neuropathy often requiring long-term immunoglobulin G (IgG) therapy for disease control. IgG can be administered intravenously (IVIg) or subcutaneously (SCIg). Increasing evidence indicates a shift toward SCIg driven by greater convenience, improved tolerability, and potential quality-of-life benefits compared with IVIg. As treatment efficacy depends on adherence, real-world data on SCIg adherence in CIDP patients are needed.

## METHODS

A US specialty pharmacy captured IgG drug delivery receipts from January 2019 to July 2023 for 23,955 patients receiving IgG therapy. Among these, 4,189 patients had CIDP (ICD-10 G61.81). Data included demographics, administration route, delivery dates, prescribed dose and frequency, and infusion pump type. This analysis focused on CIDP patients receiving exclusive SCIg therapy using KORU Medical Systems mechanical infusion pumps. Short-term adherence was assessed using validated delivery intervals; extreme outliers ( $\geq 365$ -day gaps, n=8 deliveries) were excluded.

## RESULTS

Of the 4,189 CIDP patients, 862 received SCIg and/or IVIg and 537 (62.3%) used SCIg exclusively. Pump data were available for 266 patients, of whom 232 (87.2%) used KORU pumps. Mean age was 60.6 years (range 15–98), with 50% male. Mean time on therapy was 958 days (2.6 years). A total of 5,298 SCIg deliveries were analyzed. Patients using KORU pumps refilled prescriptions every 29.4 days on average. Based on a mean month length (Gregorian Calendar) of 30.44 days, short-term adherence was calculated at 97%.



## CONCLUSIONS

This is the largest reported real-world cohort analysis of SCIg adherence in CIDP patients. High adherence associated with the use of mechanical infusion pumps supports the long-term feasibility of SCIg therapy and suggests that transitioning appropriate patients from IVIg to SCIg may improve adherence, reduce treatment burden, and enhance patient outcomes.